Media & Resources

Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity.

Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis.

NEW YORK — FEBRUARY 2, 2022 — Today IAVI announced that Wafaa El-Sadr, Alexis Pinto, and Susan Silbermann have been appointed to its board of directors. “IAVI is honored to welcome these esteemed leaders to our board,” said Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. “Their collective experience in global health research, innovation,…

Phase I trial aims to build on response seen in proof-of-concept trial.

Regulatory and public health expertise will advance the development of and global access to innovative new solutions to important global health needs.

BOSTON and NEW YORK – DECEMBER 3, 2021 – GreenLight Biosciences (ENVI) and IAVI, a non-profit scientific research organization, today announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant. “The highly mutated Omicron variant may be partially capable of eluding existing vaccines, so rapid adaptation is an urgent priority,” said…

IAVI’s extensive clinical trial experience will be combined with GreenLight COVID-19 vaccine candidate. Goal is to broaden and accelerate access to messenger RNA (mRNA) COVID-19 vaccines. Phase I trial planned for late Q1 2022. Plan speeds creation of vaccines in Africa, for Africa, and suitable for use in low-income countries globally. NEW YORK – NOVEMBER…

NEW YORK – OCTOBER 27, 2021 – IAVI announced today the award of up to US$126 million from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services to develop two recombinant vesicular stomatitis virus (rVSV)-vectored filovirus vaccine candidates. This award supports preclinical activities and includes options for…